Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis

Laryngoscope

Volumn 121, Issue 3, 2011, Pages 636-638

  Karnezis, Tom T ^a   Davidson, Terence M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Avastin; Bevacizumab; epistaxis; Hereditary hemorrhagic telangiectasia; Osler Weber rendu

Indexed keywords

BEVACIZUMAB;

ADULT; AEROSOL; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; EPISTAXIS; FEMALE; HUMAN; LASER; LASER COAGULATION; MALE; MEDICAL RECORD REVIEW; POTASSIUM TITANYL PHOSPHATE LASER; PRIORITY JOURNAL; RECURRENT DISEASE; RENDU OSLER WEBER DISEASE;

ADMINISTRATION, INTRANASAL; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPISTAXIS; FEMALE; HUMANS; INJECTIONS; LASER COAGULATION; LASERS, SOLID-STATE; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL SPRAYS; RECURRENCE; RETROSPECTIVE STUDIES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; YOUNG ADULT;

EID: 79951862329     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.21415     Document Type: Article

References (11)

1. Brunet G, Lesca G, Genin E,. Thirty years of research into Rendu-Osler-Weber disease in France: historical demography, population genetics, and molecular biology. Population Engl Ed. 2009; 64: 273-291.
2. Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2002; 19: 140-148. (Pubitemid 34121805)
3. Kjeldsen AD, Vase P, Green A,. Hereditary hemorrhagic telangiectasia [HHT]: a population-based study of prevalence and mortality in Danish HHT patients. J Intern Med 1999; 245: 31-39. (Pubitemid 29049140)
4. Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA,. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120: 838-843.
5. Shovlin CL, Guttmacher AE, Buscarinni E, et al. Diagnostic criteria for hereditary hermorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67. (Pubitemid 30127562)
6. ten Dijke P, Arthur HM,. Extracellular TGFbetal signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8: 857-869. (Pubitemid 47622560)
7. Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A,. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor β1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-828.
8. Davidson TM, Olitsky SE, Wei JL,. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010; 120: 432.
9. Simonds J, Miller F, Mandel J, Davidson TM,. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119: 988-992.
10. Bose P, Holter JL, Selby GB,. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143-2144.
11. Chen S, Karnezis TT, Davidson TM,. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia associated epistaxis. Laryngoscope (in publication).